14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PYPD vs AVTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 49.6/100 (HOLD) at $6.97 (N/M Forward P/E, -161962.7% operating margin).
Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY).
Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs AVTX. Trailing 12-month operating profitability (PYPD 0.0% vs AVTX -161962.7%) and valuation multiples (PYPD N/M vs AVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $448.7M market capitalization and -161962.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PYPD vs AVTX Key Questions & Quantitative Answers
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 49.6/100 (HOLD) at $6.97 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY). Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVTX leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $59,000 for AVTX. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.
PYPD and AVTX trade at balanced relative valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus AVTX (-33.6% ROE) capital efficiency.
In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, AVTX carries 114.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 164% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.